Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
139 Anxiety Disorders Trials near Miami, FL
Power is an online platform that helps thousands of Anxiety Disorders patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerAdapted Project BRAVE for Depression
Miami, FloridaThe overarching objective of this protocol is to (1) adapt and (2) disseminate an evidence-based, brief (approximately 30 minute) single session intervention (SSI) to better reflect the cultural and linguistic diversity of Latin, Haitian, and Haitian-American individuals via a fully online platform.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Not A Caregiver
2000 Participants Needed
Cognitive Behavioral Therapy for Mental Health Issues in Youth
Coral Gables, FloridaThe purpose of this study is to administer the Unified Protocols for Transdiagnostic Treatment of Emotional Disorders in Children (UP-C) and Adolescents (UP-A) to youth and participants' parents and to examine the efficacy and outcomes of the treatment using standardized measures, questionnaires, interviews. The UP-C and the UP-A are cognitive-behavioral therapies to treat emotional disorders.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:7 - 17
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychiatric Hospitalization, Eating Disorder, Substance-use, Others
1500 Participants Needed
ITI-1284 for Anxiety
Miami, FloridaThis is a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of ITI-1284 as monotherapy treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD in patients who have had inadequate response to generalized anxiety disorder treatment.
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
570 Participants Needed
ITI-1284 for Generalized Anxiety Disorder
Miami, FloridaThis is a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo as adjunctive therapy to GAD treatment in patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for GAD who have an inadequate response to ongoing GAD treatment.
Trial Details
Trial Status:Recruiting
Age:18+
Sex:All
705 Participants Needed
SEP-363856 for Generalized Anxiety Disorder
Miami, FloridaThis Phase 2/3 clinical trial is designed to evaluate SEP-363856 for Generalized Anxiety Disorder
Pivotal Trial
Trial Details
Trial Status:Recruiting
Age:18 - 65
Sex:All
434 Participants Needed
The purpose of this study is to look at the best ways to prevent anxiety and depression in older Latino adults who are at risk for developing anxiety and depression. Participants will be randomized to either a health promotion intervention or a healthy lifestyles education program.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
240 Participants Needed
Mobile App Support for Post-Traumatic Stress Disorder
Miami, FloridaThis study focuses on the mental health challenges faced by the World Trade Center's (WTC) General Responders due to the severe psychological trauma from the WTC collapse. PTSD and depression are among the top mental health conditions affecting these responders. Many members of the WTC Health Program (WTCHP) have relocated to Florida, making up nearly six percent of the cohort. Furthermore, many identify as Latinx, highlighting the need for services in their preferred language to promote health equity. Studies have shown that remotely-delivered, clinician-supported applications (apps) can reduce adverse MH symptoms.
PTSD Coach was developed by the Veteran's Administration as a self-managed mobile app and is available at no cost for Android and Apple devices. The primary focus of PTSD Coach is on managing PTSD symptoms. The app offers coping tools such as relaxation exercises and calming self-talk and effective sleep hygiene practices when needed. A recent review evaluated the self-managed PTSD Coach app and found it to be feasible, acceptable, and effective in reducing PTSD symptoms.
Clinician-Supported PTSD Coach was developed as a brief intervention for Veterans who were unlikely to use a mobile app on their own. Clinician Supported PTSD Coach combines PTSD Coach mobile app with four remotely-delivered 20-30 minute sessions over 8 weeks with a clinician. Studies with Veterans have reported significant reductions in PTSD and depression symptoms, treatment satisfaction and more treatment sessions attended, when compared with typical mental health care. While promising, none of these studies included WTC General Responders or focused on Latinx populations.
Given the promise of these interventions, and the need to provide support for geographically dispersed General Responders in Florida, this study aims to evaluate the feasibility, acceptability, and effectiveness of Clinician Supported PTSD Coach in reducing symptoms of PTSD, depression, anxiety, and sleep disturbances among English and Spanish-speaking WTC General Responders. Participants will be randomly assigned to one of three conditions:
1. Clinician-Supported PTSD Coach
2. Self-Managed PTSD Coach
3. Waitlist Control (no treatment until after follow-up)
Assessments will be conducted at the end of treatment (8 weeks) and at follow-up (12 weeks). The study will measure reductions in PTSD, depression, anxiety, and sleep disturbances at 8 weeks and 12 weeks. It is expected that both Clinician Supported PTSD Coach and Self-Managed PTSD Coach will reduce symptoms, with Clinician Supported PTSD Coach showing larger reductions. In addition, to assess feasibility and acceptability, the study will assess engagement, satisfaction, and barriers in both PTSD Coach app conditions.
This project aims to fill a significant gap in evidence-based mental health treatments for WTC General Responders. It responds to the WTCHP Scientific Technical Advisory Committee's call for more research on mental health interventions and addresses the critical shortage of rigorously tested app-based remote interventions for dispersed General Responders with PTSD. The study also focuses on Spanish-speaking Latinx General Responders, a group that has not been specifically targeted in previous interventions. The study's findings could lead to the development of readily deployable interventions nationally to meet the mental health needs of WTC responders and survivors, providing a valuable resource for treatment researchers and health care providers.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Age:All
Sex:All
120 Participants Needed
Medical Cannabis for Chronic Pain
Miami, FloridaThis trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stay on current meds
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:7+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Breastfeeding, Suicidality, Psychosis, Others
200000 Participants Needed
Single-Session Intervention for Child Anxiety
Coral Gables, FloridaLengthy wait times to access treatment for youth anxiety disorders is a critical issue. To help address this issue, investigators will pursue the following aims in N = 65 families on waitlists for outpatient youth anxiety psychosocial treatment. Aim 1 Pilot Phase: Develop and pilot a single session intervention (SSI) tailored for families on waitlists for outpatient psychosocial treatment for youth anxiety disorders. Investigators will pilot the single session intervention (SSI) with N = 5 families and use cognitive response interviewing to obtain data from parents and children, ensuring the content is understandable and accessible. The SSI will include psychoeducation on the cognitive behavioral conceptualization of anxiety, introduction to self-regulation strategies to manage physiological manifestations of anxiety, and cognitive restructuring of anxiogenic thoughts. The SSI will also involve parents and present strategies on how parents can support their children in managing anxious feelings and thoughts. Investigators will refine the SSI based on these data. Following the Pilot Phase, investigators will enroll an additional N = 60 families and randomize them to either the SSI (n = 30) or waitlist control (n = 30). Aim 2 Test Phase Acceptability, and Satisfaction: Examine acceptability of the refined SSI, as well as satisfaction with the SSI. Investigators hypothesize that users will find the module to be acceptable and will report high satisfaction. Aim 3 Test Phase Anxiety Outcomes: Demonstrate reductions in youth anxiety symptom severity. Investigators hypothesize that anxiety symptom severity and impairment will be significantly lower among youth who receive the refined SSI relative to youth on waitlist control. The main risk or discomfort from this research is that participants might feel uncomfortable answering questions about their behavior and feelings. Another possible risk is breach of confidentiality that could identify a participant as having elevated levels of anxiety. The benefits of this SSI would include increasing accessibility and scalability of treatment for youth anxiety disorders. Overall, this study will provide critically needed data to advance resource efficient treatment options for youth anxiety disorders.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:7 - 17
Sex:All
65 Participants Needed
ABMT for Social Anxiety Disorder
Miami, FloridaThis trial tests a computer-based therapy called ABMT on kids aged 10-14 with social anxiety. The therapy aims to help them focus less on negative social cues, which may reduce their anxiety. Researchers will compare brain activity and anxiety levels between those who get ABMT and those who do not. Attention Bias Modification Treatment (ABMT) is a novel computer-based treatment for anxiety disorders, proposed as an efficient and accessible psychological therapy.
Trial Details
Trial Status:Active Not Recruiting
Age:10 - 14
Sex:All
260 Participants Needed
Aromatherapy for Pre-Procedure Anxiety
Miami, FloridaThe goal of this study is to evaluate the effect of lavender essential oil on pre-procedure anxiety for patients undergoing ultrasound guided musculoskeletal procedures
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 85
Sex:All
Key Eligibility Criteria
Disqualifiers:Impaired Smell, Asthma, Migraines, Others
Must Not Be Taking:Benzodiazepines
48 Participants Needed
Naltrexone/Acetaminophen for Migraine Headaches
North Miami, Florida* This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo. In Stage 2 (dose-finding), they will test three doses of the combination. Before both stages, participants will complete a run-in period, documenting a migraine attack without study medication. They will then treat one migraine attack in each stage.
* 4 visits
* Requirements: Migraine Diagnosis. BMI below 34. Read, write, and speak English. No opioids, marijuana, benzodiazepines, or excessive alcohol.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 75
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Hypertension, Diabetes, Others
Must Not Be Taking:Opioids, Benzodiazepines, Barbiturates, Others
300 Participants Needed
BNC210 for Social Anxiety Disorder
Miami Lakes, FloridaThe purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using the Subjective Units of Distress Scale (SUDS) in adult patients with social anxiety disorder.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Alcohol-use, Others
Must Not Be Taking:Psychotropics, Benzodiazepines
332 Participants Needed
PROSOMNIA Sleep Therapy for Chronic Insomnia
Hollywood, FloridaThis clinical trial aims to evaluate the safety and efficacy of PROSOMNIA Sleep Therapy (PSTx) for individuals suffering from chronic insomnia, sleep deprivation, and REM sleep disorders. Chronic insomnia, characterized by difficulty falling or staying asleep, significantly affects patients and quality of life, mood, and cognitive function. REM sleep disorders, in which the body struggles to enter or maintain restful REM sleep, can worsen these issues. The trial introduces a novel therapy using anesthesia-induced sleep, targeting sleep homeostasis and improving sleep architecture.
Objectives: The primary goals of the trial are to determine:
1. Whether PROSOMNIA Sleep Therapy increases the quality of REM sleep.
2. Whether PSTx increases the duration of REM and/or NREM sleep.
3. Whether PSTx decreases the time it takes participants to fall asleep (sleep onset latency).
Participants will receive ONE (1) PROSOMNIA Sleep Therapy session lasting between 60-120 minutes. Each session uses Diprivan/Propofol to induce sleep, and is monitored via an EEG to ensure proper sleep stages, particularly REM sleep.
Participant Criteria:
Inclusion: Adults aged 18-65 with diagnosed or undiagnosed chronic insomnia or sleep deprivation.
Exclusion: Patients with severe obesity, significant cardiovascular, neurological, or psychiatric conditions, or those with an ASA status above II.
Study Design: This trial is non-randomized, single-arm and open-label, with all participants receiving the PSTx. The trial does not include a comparison group, as the focus is on evaluating the immediate, direct effects of the therapy.
Participants will undergo continuous EEG monitoring during therapy sessions, allowing researchers to track brain activity and sleep stages in real-time. This method ensures that sleep cycles, particularly REM sleep, are optimized for therapeutic benefit.
Therapy Methodology:
PROSOMNIA Sleep Therapy leverages anesthesia to mimic natural sleep patterns and enhance the efficiency of REM sleep. Diprivan/Propofol is used to induce REM sleep, while EEG monitoring tracks and maintains proper sleep architecture throughout the session. The therapy promotes the clearance of adenosine, a compound that builds up during wakefulness and drives the need for sleep. Adenosine is cleared during REM sleep, reducing sleep pressure and improving cognitive function.
Outcome Measures:
Primary Outcomes: Researchers will measure the increase in REM sleep duration, improvement in sleep quality (via self-reported questionnaires), and a reduction in sleep onset latency.
Secondary Outcomes: These include changes in mood, cognitive function, and blood serum uric acid levels. Patient-reported outcomes will also be tracked through tools like the PROSOMNIA Sleep Quiz, which is specifically designed for PSTx.
Significance: Chronic insomnia and REM sleep disorders affect millions globally, leading to cognitive impairment, mood disturbances, and poor overall health. Traditional treatments, including pharmacological approaches and Cognitive Behavioral Therapy for Insomnia (CBT-I), often provide suboptimal results for many individuals. PSTx offers a novel, therapeutic approach to restoring sleep balance and enhancing the overall quality of sleep, particularly for those who have not responded to conventional treatments.
Study Process:
Recruitment and Baseline Assessments: Participants undergo a comprehensive sleep assessment, including sleep questionnaires and polysomnography, to establish a baseline for sleep quality and duration. Blood serum uric acid levels will also be measured to track any biochemical changes due to therapy.
Therapy Sessions: Only one (1) PROSOMNIA Sleep Therapy session will be administered, with the session lasting between 60-120 minutes. Diprivan/Propofol is used to induce sleep, and EEG will monitor brain activity to ensure the proper balance of sleep stages.
Post-Therapy Follow-up: Follow-up assessments will occur at 24 hours, 7 days, and 30 days post-treatment. Researchers will analyze the therapy effects on REM sleep, mood, cognitive function, and other health indicators.
Potential Implications: If successful, this trial could revolutionize how we treat sleep disorders by targeting the underlying mechanisms of sleep pressure and REM sleep disruption. PROSOMNIA Sleep Therapy may offer a safe, effective, and immediate alternative for patients who have exhausted other treatment options.
Key Concepts:
Homeostatic sleep drive, (Process S), caused by adenosine buildup during wakefulness, is disrupted by chronic insomnia. This impacts cognitive function health and recovery. Anesthesia-induced REM sleep via PSTx helps regulate this homeostatic sleep stage, offering deeper and more restorative sleep compared to other sleep therapies. The study uses statistical methods like ANOVA and Chi-square to measure outcomes.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 1
Age:18 - 65
Sex:All
100 Participants Needed
Online Mental Health Coaching for Anxiety and Depression
Fort Lauderdale, FloridaThe purpose of this research study is to provide a free 6-week, online psychological coaching program to NSU undergraduate students to help with anxiety, depression, and stress, while improving quality of life and healthy coping skills.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Non-NSU Students, Under 18, Psychotherapy, Others
160 Participants Needed
The purpose of this trial is to examine the preliminary clinical efficacy of CYB004 participants with GAD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Sex:All
36 Participants Needed
ENX-102 for Generalized Anxiety Disorder
Lakeland, FloridaThis trial is testing a new medication called ENX-102 to see if it can help people with generalized anxiety disorder by reducing their anxiety symptoms.
Trial Details
Trial Status:Recruiting
Age:18 - 65
Sex:All
280 Participants Needed
This Phase 3 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement.
In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Alcohol Use, Others
Must Not Be Taking:Psychotropics, CBD, Herbal
236 Participants Needed
MM120 for Anxiety
Bradenton, FloridaA Phase 3, Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Panorama
Pivotal Trial
Trial Details
Trial Status:Recruiting
Age:18 - 74
Sex:All
Key Eligibility Criteria
Disqualifiers:Psychiatric Disorders, Alcohol Use, Others
250 Participants Needed
MM120 for Anxiety
Orlando, FloridaThe reason for this study is to see if the investigational study drug, called MM120, can help people with Anxiety compared to a placebo. A placebo is an inactive drug that looks like MM120 but does not contain any active ingredients.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Age:18 - 74
Sex:All
198 Participants Needed
This Phase 3 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement.
In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Alcohol Use, Others
Must Not Be Taking:Psychotropics, CBD, Herbal
236 Participants Needed
This Phase 2 clinical trial is designed to evaluate the Fasedienol Nasal Spray (fasedienol) for adults that are 18-65 who suffer from symptoms of social anxiety such as nervousness, worry or fear of judgement.
In addition, there is an Open Label Extension phase of the study for patients that choose to participate where use of nasal spray for up to 12 months will be assessed.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Sex:All
60 Participants Needed
Muscadine Wine Polyphenols for Cognitive Functioning
Gainesville, FloridaPrevious studies have shown that polyphenol-rich foods can positively affect cognitive functions, memory, and mood in humans. We hypothesize that both acute and chronic intake of muscadine wine polyphenols will improve cognitive performance and mood through regulating the HPA axis, alleviating inflammation and oxidative stress, and/or inhibiting monoamine oxidase activities
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 65
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Diabetes, Mental Illnesses, Others
Must Not Be Taking:Psychostimulants, Cannabis Products
25 Participants Needed
Lavender Aromatherapy for Procedural Anxiety and Pain
Gainesville, FloridaOffice hysteroscopy is an invaluable practice to treat a myriad of gynecological processes. However, a limiting factor is the perceived pain and anxiety. In a randomized pilot study, treatment with lavender aromatherapy will significantly decrease the stress/anxiety levels associated with office hysteroscopy, as measured on a visual analogue scale and the Hospital Anxiety and Depression Scale (HADS) questionnaire when compared to control subjects receiving distilled water placebo.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 99
Sex:Female
Key Eligibility Criteria
Disqualifiers:Pelvic Infection, Cancer, Hypertension, Others
40 Participants Needed
CBD for Anxiety
Gainesville, FloridaThis study will examine the doses, safety, and test the preliminary efficacy of hemp-derived CBD product for improving anxiety symptoms and sleep disturbances among individuals with anxiety. A 4-week, randomized, double-blind, placebo-controlled trial will be conducted to determine the safety, tolerability, preliminary efficacy, and acceptability of 50 to 150 mg/day of CBD. The treatment period will consist of a two-week titration period followed by a 2- week maintenance period. In addition, the study seeks to examine whether changes in sleep disturbances precede changes in anxiety symptoms.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 55
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, Suicidal Behavior, Liver Disease, Others
Must Not Be Taking:Benzodiazepines, Opioids, Antihistamines, Others
30 Participants Needed
Safety Behavior Fading for Body Dysmorphic Disorder
Tallahassee, FloridaThe current study aims to explore the efficacy of a text message based safety behavior fading intervention compared to a relaxing video intervention for appearance concerns.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65
Sex:All
400 Participants Needed
Computerized Anxiety Treatment for Mild Alzheimer's Disease
Tallahassee, FloridaThe goal of this clinical trial is to test the effectiveness of a computerized anxiety sensitivity treatment (CAST) compared to a health education control (HEC) in older adults with mild cognitive impairment (MCI) or mild Alzheimer's Disease and related dementias (ADRD) and their care partners. The main questions it aims to answer are:
1. Efficacy of CAST in reducing anxiety and related symptoms among those with MCI/mild ADRD
2. Efficacy of CAST in reducing care partner burden among care partners of people living with MCI/mild ADRD
3. Explore treatment mechanisms using a multi-modal assessment battery of anxiety sensitivity and anxiety
Participants will complete six in-person visits including a baseline assessment, two intervention sessions, and three follow-up assessments at 1, 3, and 6-months posttreatment. Participants will also complete three weeks of ecological momentary assessments (EMAs) for one week prior to intervention, one week between intervention sessions, and one week after intervention.
If there is a comparison group: Researchers will compare CAST to HEC to see if CAST reduces anxiety and related symptoms in older adults with MCI/mild ADRD and care partner burden to a greater degree than HEC.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:60+
Sex:All
Key Eligibility Criteria
Disqualifiers:Severe Mental Illness, Others
388 Participants Needed
Tributyrin for Health and Performance
Tallahassee, FloridaThe purpose of this study is to determine if tributyrin supplementation improves metabolite concentrations, overall health biomarkers, and performance in sedentary men and women. The study would further understand the potential usage of tributyrin as a health and performance increasing supplement through improving gut and immune health, sleep, and performance as well as reduce inflammation. Participants will supplement for tributyrin for 4 weeks and complete fecal metabolite measures, cardiovascular evaluation, sleep assessment, and exercise testing as well as provide blood samples.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 50
Sex:All
Key Eligibility Criteria
Disqualifiers:Metabolic, Cardiovascular, Gastrointestinal, Others
Must Not Be Taking:Microbiome Supplements
20 Participants Needed
Computerized Psycho-social Intervention for Anxiety Disorders
Tallahassee, FloridaAnxiety disorders are the most common form of psychopathology, and frequently begin in childhood, resulting in lifelong impairment. Increased brain activity after making mistakes, as reflected by the error-related negativity (ERN), is observed in people with anxiety disorders, even before disorder onset. The ERN is therefore of great interest as a potentially modifiable risk factor for anxiety. However, methodological issues can make the ERN difficult to measure.
Increased brain activity in response to a balance disturbance, as reflected by the balance N1, resembles the ERN, but does not share its methodological issues. The investigators' preliminary data demonstrate that the balance N1 and the ERN are associated in amplitude in adults, suggesting they may depend on the same brain processes. The balance N1 has never been investigated in individuals with anxiety disorders, but it increases in amplitude within individuals under anxiety-inducing environmental contexts. Further, balance and anxiety are related in terms of brain anatomy, daily behavior, disorder presentation, and response to treatment.
The present investigation will measure the ERN and the balance N1 in children (ages 9-12) with anxiety disorders, and further, how these brain activity measures change in response to a brief, 45-minute, computerized psychosocial intervention that was developed to reduce reactivity to errors, and has been shown to reduce the ERN. The investigators will recruit approximately 80 children with anxiety disorders, half of whom will be randomly assigned to the active intervention condition. The other half will be assigned to an active control condition, consisting of a different 45-minute computerized presentation. Participants assigned to the control condition can access the computerized intervention after participation in the study.
The purpose of this investigation is to test the hypothesis that the balance N1 and the ERN will be reduced to a similar extent after the intervention, to demonstrate that these brain responses arise from shared brain processes. Transfer of the effect of the psycho-social intervention to the balance N1 would provide insight into prior work demonstrating that balance training can alleviate anxiety in young children, and well-documented benefits of psychotherapy to balance disorders. Collectively, these data may guide the development of multidisciplinary interventions for the prevention and treatment of anxiety disorders in children.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:9 - 12
Sex:All
Key Eligibility Criteria
Disqualifiers:Depression, ADHD, Severe Psychopathology, Others
80 Participants Needed
Text Messages for Social Anxiety
Tallahassee, FloridaThe current study aims to explore the efficacy of a text message based Safety Behavior Fading Intervention compared to an active control intervention.
No Placebo Group
Trial Details
Trial Status:Recruiting
Age:18 - 65
Sex:All
124 Participants Needed
Page 1 of 5+
Learn More About Power
My name is Bask, and I helped to start the company here. We started Power when my Dad was diagnosed with multiple myeloma, and I needed a better way to understand how he could access the most promising immunotherapy for his illness.
Bask GillCEO at Power
Frequently Asked Questions
How much do Anxiety Disorders clinical trials in Miami, FL pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Anxiety Disorders clinical trials in Miami, FL work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Anxiety Disorders trials in Miami, FL 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Miami, FL for Anxiety Disorders is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Miami, FL several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Anxiety Disorders medical study in Miami, FL ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Anxiety Disorders clinical trials in Miami, FL ?
Most recently, we added Pediatric Palliative Care for Rare Diseases, Calm Moms-V for PTSD in Pregnant Veterans and Pregnenolone for Anxiety and Depression to the Power online platform.
What do the "Power Preferred" and "SuperSite" badges mean?
We recognize research clinics with these awards when they are especially responsive to patients who apply through the Power online platform. SuperSite clinics are research sites recognized for a high standard of rapid and thorough follow-up with patient applicants. Meanwhile, Power Preferred clinics are the top 20 across the entire Power platform, recognized for their absolute top patient experience.
Which clinics have received Power Preferred and SuperSite awards recruiting for Anxiety Disorders trials in Miami, FL ?
The Anxiety Disorders clinics in Miami, FL currently recognized as Power Preferred are: Accel Research Sites-LKD CRU (Alcanza) in Lakeland, Florida Houston Mind and Brain in Houston, Texas The Anxiety Disorders clinics in Miami, FL currently recognized as SuperSites are: Clinical Neuroscience Solutions, Inc. in Jacksonville, Florida CenExel ACMR in Atlanta, Georgia